


URAT1 inhibitor 4

Cat. No.:	HY-152033
CAS No.:	2700292-02-8
Molecular Formula:	C ₂₇ H ₂₀ BrN ₃ O ₄ S ₃
Molecular Weight:	626.56
Target:	URAT1; GLUT
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active URAT1 inhibitor with an IC ₅₀ of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258) ^[1] .																
IC₅₀ & Target	IC ₅₀ : 7.56 ± 0.52 μM (URAT1), 55.96 ± 10.38 μM (GLUT9) ^[1]																
In Vitro	URAT1 inhibitor 4 (compound 10) inhibits URAT1 and GLUT9 with IC ₅₀ s of 7.56 ± 0.52 μM and 55.96 ± 10.38 μM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
In Vivo	<p>URAT1 inhibitor 4 (2 mg/kg; p.o.; single dosage) decreases serum uric acid level in acute hyperuricemia model mice^[1]. URAT1 inhibitor 4 (1000 mg/kg; i.g.; single dosage) exhibits higher survival rate than Lesinurad in mice acute toxicity assessment^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Kunming mice (acute hyperuricemia model)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o.; single dosage</td> </tr> <tr> <td>Result:</td> <td>Decreased serum uric acid with an decrease ratio of 73.29%.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Kunming mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1000 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.g.; single dosage</td> </tr> <tr> <td>Result:</td> <td>Survival rate was 100% after 7 days, while Lesinurad were 40% (male) and 20% (female).</td> </tr> </table>	Animal Model:	Kunming mice (acute hyperuricemia model) ^[1]	Dosage:	2 mg/kg	Administration:	p.o.; single dosage	Result:	Decreased serum uric acid with an decrease ratio of 73.29%.	Animal Model:	Kunming mice ^[1]	Dosage:	1000 mg/kg	Administration:	i.g.; single dosage	Result:	Survival rate was 100% after 7 days, while Lesinurad were 40% (male) and 20% (female).
Animal Model:	Kunming mice (acute hyperuricemia model) ^[1]																
Dosage:	2 mg/kg																
Administration:	p.o.; single dosage																
Result:	Decreased serum uric acid with an decrease ratio of 73.29%.																
Animal Model:	Kunming mice ^[1]																
Dosage:	1000 mg/kg																
Administration:	i.g.; single dosage																
Result:	Survival rate was 100% after 7 days, while Lesinurad were 40% (male) and 20% (female).																

REFERENCES

[1]. Zhang J, et al. Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors. Eur J Med Chem. 2022 Dec 15;244:114816.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA